7 JCI-accredited hospitals · 45+ hospitals & clinics · 90+ countries served · 24/7 multilingual support
Rheumatology & Autoimmune

Why Lung Function Tests and Echocardiography Come Early in Scleroderma Treatment

22 min read
Why Lung Function Tests and Echocardiography Come Early in Scleroderma Treatment

Key Takeaways

  • In systemic sclerosis the two complications most likely to cause serious harm, interstitial lung disease and pulmonary hypertension, usually develop before any breathlessness is felt.
  • The diffusing capacity (DLCO) is the single lung test value most sensitive to early change, and a DLCO that falls while FVC stays normal points toward blood vessel disease rather than scarring.
  • An echocardiogram estimates pulmonary artery pressure from the speed of blood leaking across the tricuspid valve; only right heart catheterization measures it directly and confirms the diagnosis.
  • High-resolution CT, not spirometry, confirms pulmonary fibrosis, and lung biopsy is rarely needed when the CT pattern is typical in a person with known scleroderma.
  • Localized scleroderma (morphea) does not involve internal organs and is not normally screened for lung or heart disease, unlike systemic sclerosis.
  • Guidelines generally advise repeating lung function tests and echocardiography at least yearly in systemic sclerosis, because a normal first result is a baseline, not a discharge.
Quick Answer

Lung function tests and echocardiography are ordered early in scleroderma because the two complications most likely to shorten life, interstitial lung disease and pulmonary hypertension, usually begin silently. Breathing tests can detect falling lung capacity or reduced gas transfer before any breathlessness, and a heart ultrasound can flag pressure strain in the right heart. Together they create a baseline that guides monitoring and treatment decisions with the care team.

She came for an appointment about her fingers. For a year they had turned white in the cold, then purple, and lately the skin over the knuckles had grown shiny and tight. The rheumatologist listened, examined her hands, then said something she had not expected: before anything else, she would need a breathing test and an ultrasound of her heart.

That sequence surprises almost everyone who hears the words systemic sclerosis for the first time. Why order a scleroderma lung function test and echocardiogram when the lungs feel fine and the heart has never missed a beat? The answer sits in how this disease behaves. Scleroderma scars tissue and narrows small blood vessels, and the lungs and the pulmonary circulation are among its favorite targets.

The frustrating part is that the early damage is quiet. People often feel well right up until the point where a staircase leaves them winded. Testing early is how clinicians refuse to wait for that moment.

Does scleroderma cause lung issues?

Yes, and the lungs are the reason this question gets asked so soon after diagnosis. Scleroderma, called systemic sclerosis when it affects internal organs, is an autoimmune condition in which the immune system drives two processes at once: overproduction of collagen, the protein that forms scar tissue, and damage to the lining of small blood vessels. Skin thickening is the visible sign. The same two processes happen out of sight in the chest.

Two complications matter most. The first is interstitial lung disease, scarring and inflammation in the delicate tissue between the air sacs that normally lets oxygen pass into the blood. The second is pulmonary hypertension, abnormally high pressure in the arteries that carry blood from the right side of the heart through the lungs. According to Cleveland Clinic and Mayo Clinic, these lung and heart complications are the leading causes of serious illness in systemic sclerosis, which is why rheumatology guidelines place chest assessment at the front of the care pathway rather than the back.

The heart can be involved in a third way, too. Scar tissue can form in the heart muscle itself, and fluid can collect in the sac around it. An echocardiogram looks for both.

None of this means every person with scleroderma develops lung disease. Mayo Clinic notes that the condition takes different forms, with limited disease mostly confined to the skin of the hands, forearms and face, and diffuse disease spreading more widely and more quickly. Both forms carry some lung risk, but the pattern differs, and early testing is how the team learns which pattern applies to one particular person rather than to a textbook average.

What a scleroderma lung function test actually measures

A lung function test, also called a pulmonary function test, is a set of breathing measurements taken while you sit in a booth or at a bench and blow into a mouthpiece connected to a machine. MedlinePlus describes the three parts that matter most in scleroderma.

Doctor consulting patient with inhaler in clinic: What a scleroderma lung function test actually measures

Spirometry comes first. You take the deepest breath you can and blow out as hard and as long as possible. The volume you exhale is the forced vital capacity, or FVC. Scarred lungs become stiff and hold less air, so a falling FVC is the classic signature of restriction.

Lung volumes come next, usually measured in a clear plastic booth called a body plethysmograph. These capture total lung capacity, including the air you cannot blow out, which sharpens the picture of whether the lungs are truly shrinking.

The third measurement is the one many people have never heard of: the diffusing capacity for carbon monoxide, written DLCO. You inhale a harmless trace of carbon monoxide mixed with air, hold your breath for about ten seconds, then exhale. The machine calculates how much gas crossed from the air sacs into the blood. DLCO measures the health of the gas-exchange surface and the small vessels behind it.

That last point is why DLCO earns special attention in scleroderma. A low FVC with a proportionally low DLCO points toward scarring. A near-normal FVC with a markedly low DLCO raises a different question: are the blood vessels, rather than the lung tissue, the problem? That pattern is one of the earliest clues to pulmonary hypertension, and it is one reason the breathing test and the heart ultrasound are read side by side rather than separately.

What the echocardiogram for scleroderma is looking for

An echocardiogram is an ultrasound of the heart. A technologist spreads gel on your chest and moves a handheld probe across it while sound waves bounce back to build moving images. Mayo Clinic notes that a standard transthoracic study involves no radiation, needs no special preparation and usually takes under an hour.

In most settings an echo is ordered to check the left side of the heart, the pumping chamber that supplies the body. In scleroderma, the right side gets equal billing. The right ventricle pushes blood through the lungs, and if pressure in the pulmonary arteries rises, that chamber has to work against resistance it was never built for. On ultrasound it may look enlarged, its wall thickened, its squeeze weaker.

The technologist also measures the speed of a tiny leak across the tricuspid valve, the valve between the right atrium and right ventricle. Almost everyone has a trace of this leak. Its velocity lets the machine estimate the pressure in the pulmonary artery. That estimate is the single echo number clinicians watch most closely in scleroderma, though, as a later section explains, it is an estimate and not a diagnosis.

Other findings matter as well. Fluid in the pericardium, the sac around the heart, can appear in systemic sclerosis. Stiffness of the left ventricle during its filling phase, called diastolic dysfunction, can raise pulmonary pressures through a completely different mechanism. The heart muscle itself can show subtle changes from scarring.

Put plainly, the echocardiogram is a map of how the heart is coping with whatever the lungs and their vessels are doing. It cannot see the lung tissue, which is why it never replaces the breathing test.

Why both tests come early, before any symptoms appear

The honest reason is that symptoms are a poor alarm system for this disease. Breathlessness tends to arrive only when a substantial amount of lung reserve has already been lost, and fatigue is so common in scleroderma for other reasons that it rarely points anywhere specific. Waiting for a complaint means waiting for damage.

Doctor consulting patient with food and ultrasound equipment: Why both tests come early, before any symptoms appear

Early testing solves two problems. It establishes a baseline, a personal normal against which every later test can be compared. A single FVC reading tells you little on its own; a reading that has dropped meaningfully since last year tells you a great deal. The same is true of DLCO and of estimated pulmonary pressures on echo.

The second problem is timing of treatment. Lung scarring, once formed, does not reverse. Medicines used for scleroderma lung disease aim to slow or stabilize the process, so they have the most to protect when the lungs still have the most to lose. Finding interstitial lung disease early, or spotting the vascular pattern that precedes pulmonary hypertension, widens the window in which the care team can act.

Screening programs reflect this logic. Several international rheumatology and respiratory bodies advise that people with systemic sclerosis have lung function testing and echocardiography at diagnosis and then on a regular schedule, commonly yearly, even when they feel well. Some centers use structured algorithms, such as the DETECT score, which combine DLCO, blood markers and other findings to decide who needs closer heart assessment.

The pattern should feel familiar. A person with diabetes has an eye exam before vision changes. A person with scleroderma has lung and heart tests before breathlessness. In both cases the goal is to act on the trend, not the crisis.

Who is usually tested first, and who is usually asked to wait

Nearly everyone with a diagnosis of systemic sclerosis is offered both tests soon after the diagnosis is made. Within that group, some people are moved to the front of the queue because their risk of lung involvement is higher.

Diffuse cutaneous disease, where skin thickening extends above the elbows and knees or onto the trunk, carries a higher likelihood of interstitial lung disease, particularly in the first few years. Certain antibodies found in blood tests shift the odds as well: anti-topoisomerase antibodies, also called anti-Scl-70, are associated with lung scarring, while anticentromere antibodies are more often linked with limited skin disease and a later risk of pulmonary hypertension. A low DLCO on a first test, a dry cough or crackles heard at the lung bases on examination also prompt faster or fuller investigation.

Who is usually asked to wait? Two groups. People with localized scleroderma, called morphea, have patches of hardened skin without internal organ involvement, and NHS guidance describes it as a separate, milder condition. They are not normally screened for lung disease unless something else raises concern. The second group is anyone with an acute illness. Spirometry demands a maximal effort, and MedlinePlus notes it may be postponed after a recent chest infection, chest surgery, heart attack or eye surgery, where forceful blowing could be unsafe or produce misleading numbers.

Children with systemic sclerosis follow a similar pathway, with testing adapted to age and ability to follow instructions. Pregnancy is not a reason to skip either test; both are safe, and a baseline is especially useful when the heart and lungs are about to carry extra load.

Lung function test vs echocardiogram: what each one shows

People often assume the two tests overlap. They barely do. One measures the lungs and their gas-exchange surface; the other watches the heart coping with the circulation that runs through them. The table sets them side by side.

Feature Lung function test Echocardiogram
What it is Breathing measurements into a mouthpiece Ultrasound of the heart through the chest wall
Key numbers in scleroderma FVC, total lung capacity, DLCO Right ventricle size and function, estimated pulmonary artery pressure, pericardial fluid
Mainly screens for Interstitial lung disease; vascular pattern when DLCO falls alone Pulmonary hypertension; heart muscle and pericardial involvement
What it cannot do Show the lung tissue or confirm fibrosis Measure pulmonary pressure directly or see lung tissue
Radiation None None
Typical duration Often under an hour (MedlinePlus) Usually under an hour (Mayo Clinic)
Effort required Maximal breathing maneuvers, repeated Lying still, occasional breath holds
Next step if abnormal High-resolution CT of the chest Right heart catheterization

Two patterns are worth remembering. When FVC and DLCO fall together, the suspicion is scarring and the next step is a CT scan. When DLCO falls while FVC holds steady, or when the echo shows a rising pressure estimate, the suspicion turns to the blood vessels and the next step is a direct pressure measurement.

Neither test gives a final answer by itself. Their value is that they are safe enough to repeat often and sensitive enough to catch change, which is precisely what long-term monitoring of a scarring disease requires.

What chronic interstitial lung disease means in scleroderma

The interstitium is the thin scaffolding between the air sacs of the lung, threaded with the smallest blood vessels. Interstitial lung disease is an umbrella term for conditions that inflame and thicken that scaffolding. MedlinePlus lists more than a hundred causes, from dust exposures to medicines to autoimmune diseases. Systemic sclerosis is one of the autoimmune causes, and the resulting condition is usually called scleroderma interstitial lung disease.

Chronic simply means long-lasting. In practice it signals that the process is unlikely to disappear on its own, and that the care plan is about control rather than a short course of treatment. What varies enormously is pace. Some people have mild changes on a CT scan that remain stable for years. Others see a steady decline in FVC over months. A smaller group experience rapid progression. Clinicians cannot reliably tell these groups apart at the first visit, which is another argument for a solid baseline and regular repeat testing.

The scarring in scleroderma tends to follow a pattern radiologists call nonspecific interstitial pneumonia, with more inflammation and ground-glass haze and less of the dense honeycomb destruction seen in some other lung diseases. That distinction has practical weight, because the inflammatory component is the part treatment aims to quiet.

Symptoms, when they come, are usually a dry cough and breathlessness on exertion that creeps up slowly. Many people adjust without noticing, taking the elevator, walking a little slower. That adaptation is exactly why the breathing test, which cannot be negotiated with, is more trustworthy than how someone feels on the day.

How do you confirm pulmonary fibrosis once a test looks abnormal?

A lung function test raises suspicion. It does not confirm anything. Confirmation of scarring, or pulmonary fibrosis, rests on imaging, and the imaging that matters is a high-resolution CT scan of the chest, usually written HRCT.

A CT scanner takes cross-sectional X-ray pictures of the lungs. The high-resolution protocol uses thinner slices so radiologists can see the fine texture of lung tissue. In scleroderma they look for ground-glass opacity, a hazy veil that often reflects inflammation; reticulation, a fine net pattern that reflects thickened interstitium; traction bronchiectasis, airways pulled wide by surrounding scar; and honeycombing, clusters of small cysts marking end-stage fibrosis. The extent of these changes, often concentrated at the bases of the lungs, is described in the report alongside the pattern.

The scan does involve a small radiation dose, which is why it is not used for routine yearly screening in the way breathing tests are. Instead it is ordered at diagnosis in many centers, and again when lung function changes or symptoms shift.

Lung biopsy, removing a sample of tissue for the microscope, is rarely needed. In a person with established systemic sclerosis and a typical CT appearance, the diagnosis is usually clear without it, and the risks of a surgical biopsy generally outweigh the information it would add.

Two further measures round out the assessment. A six-minute walk test records how far you can walk at your own pace and whether your oxygen level dips, which reflects real-world capacity. Blood oxygen measurement at rest and on exertion can expose a gap between a reassuring FVC and what the body experiences. Many centers then review all of this together in a multidisciplinary meeting, with rheumatologists, chest physicians and radiologists reaching a shared conclusion.

Pulmonary hypertension in scleroderma: why echo is a screen, not the final word

Pulmonary hypertension means high blood pressure in the arteries of the lungs, a separate system from the arm-cuff blood pressure most people know. Cleveland Clinic explains that current international definitions set the threshold at a mean resting pressure above 20 mmHg in the pulmonary artery, measured directly.

Measured directly is the phrase that matters. The echocardiogram estimates pulmonary pressure from the speed of blood leaking back across the tricuspid valve. That estimate is useful and non-invasive, but it depends on image quality, on the operator being able to capture the jet, and on an assumption about pressure in the right atrium. It can run too high in some people and too low in others, and in a small number no measurable jet is found at all.

Confirmation therefore requires right heart catheterization. A thin tube is passed through a vein, usually in the neck or groin, into the right side of the heart and out into the pulmonary artery, where pressures are read directly. Mayo Clinic describes it as the definitive test. It is performed under local anesthetic with monitoring, and most people go home the same day.

The catheter study answers a second question the echo cannot: which type of pulmonary hypertension this is. In scleroderma there are three common routes. Pulmonary arterial hypertension, where the small lung arteries themselves narrow and stiffen. Pulmonary hypertension secondary to interstitial lung disease, where scarred lung tissue drives the pressure up. And pulmonary hypertension from stiffness of the left heart, which backs pressure up into the lungs from behind. These routes respond to different treatment approaches, so telling them apart changes what the care team does next.

What the following days and weeks usually look like

There is no recovery period after either test. The breathing maneuvers can leave you lightheaded or briefly tired, and a few people feel a little chest achiness from repeated hard exhalations, but both settle within minutes. The echo leaves nothing behind except gel to wipe off.

Results follow a two-step path. The technologist records the raw measurements on the day, but interpretation belongs to a physician, who compares your numbers against predicted values for your age, sex, height and ethnicity and, where available, against your own earlier results. Many clinics review the findings at the next scheduled appointment, typically within a few weeks, unless something urgent appears, in which case you would be contacted sooner.

If the lung function pattern suggests restriction or low gas transfer, expect a referral for a high-resolution CT scan and possibly a six-minute walk test. If the echocardiogram shows a raised pressure estimate or a strained right ventricle, expect a discussion about right heart catheterization and a review of blood tests, including a heart strain marker called NT-proBNP that tends to rise when the right heart is under load.

If both tests are reassuring, the plan is usually to repeat them on a schedule. Guidelines from rheumatology and respiratory societies commonly advise yearly lung function testing and echocardiography for people with systemic sclerosis, with shorter intervals in the first years after diagnosis or when risk is higher. Your team may set a different rhythm based on your antibody profile, skin subtype and how stable earlier results have been.

Between tests, the most useful thing you can do is notice change. New breathlessness on a route you usually manage, a cough that lingers, swelling of the ankles: these are reasons to bring a test forward rather than wait for the calendar.

What the results change about scleroderma treatment

The point of testing early is that the findings shape decisions, and the decisions sit with the treating team. In broad, guideline-level terms, here is how the results steer the conversation.

When interstitial lung disease is confirmed and judged to be active or progressive, clinicians generally consider two classes of medicine. Immunosuppressants dampen the immune activity driving inflammation in the lung scaffolding. Antifibrotic drugs act on the signaling pathways that turn inflammation into permanent scar. Both aim to slow decline rather than restore lost capacity, and their effect is judged over months by repeating the same FVC and DLCO measurements that prompted treatment in the first place. Which class, whether to combine them, and when to start are judgments that weigh lung findings against skin, gut and kidney involvement and against side-effect risk.

When pulmonary arterial hypertension is confirmed by catheterization, treatment moves toward medicines that relax and widen the small lung arteries through several different chemical pathways. Choice and combination depend on severity and on the type of pulmonary hypertension identified. Where pressure is driven mainly by lung scarring or left heart stiffness, the approach differs, which is why the catheter study matters so much.

Some measures apply regardless of results. Keeping vaccinations current, since chest infections hit scarred lungs harder. Treating acid reflux, which is common in scleroderma and may irritate the lungs through small aspirations. Pulmonary rehabilitation, a supervised exercise and education program, for anyone with reduced capacity. Supplemental oxygen when levels fall. Stopping smoking, if relevant.

Never adjust, start or stop a prescribed medicine on the basis of a test result you have read yourself. Numbers in isolation mislead; the trend and the whole picture are what your team interprets.

What people often get wrong about scleroderma lung and heart testing

“I can breathe fine, so my lungs must be fine.” This is the most common and the most costly assumption. Lung reserve is large, and symptoms typically appear only after a meaningful share of it is gone. The breathing test exists precisely because feeling well is not evidence of healthy lungs.

“The echo showed high pressure, so I have pulmonary hypertension.” An echocardiogram estimates pressure; it does not measure it. A raised estimate is a reason for further assessment, usually right heart catheterization, not a diagnosis in itself. The reverse holds too: a normal estimate lowers but does not eliminate the possibility.

“My tests were normal, so I’m done.” Normal at one point in time is a baseline, not a discharge. Scleroderma lung disease and pulmonary hypertension can develop years after diagnosis, which is why guidelines favor repeated screening rather than a single check.

“These tests are risky or involve radiation.” Neither does. Spirometry and echocardiography are among the safest investigations in medicine. The CT scan that may follow an abnormal result does carry a small radiation dose, which is why it is used selectively.

“Localized scleroderma carries the same lung risk.” Morphea affects skin and sometimes underlying tissue. NHS guidance describes it as a distinct condition that does not involve internal organs, so routine lung screening is not usually part of its care.

“A slightly low DLCO means I have fibrosis.” DLCO falls for many reasons, including anemia, smoking history and vessel disease without scarring. It is a prompt for a closer look, not a verdict.

“Early treatment will bring my lung function back to normal.” Current treatments aim to slow or stabilize. Scar tissue that has formed is not reversed, which is the strongest argument for finding disease before much has formed.

Questions to ask your care team about scleroderma pulmonary function tests and echo

A test is only as useful as the conversation around it. These questions tend to surface the information that matters most, and writing them down beforehand helps when the appointment moves quickly.

  • Which subtype of scleroderma do I have, and which antibodies were found? How do those shape my lung and heart risk?
  • What were my actual FVC and DLCO values, and what percentage of predicted do they represent? Can I have a copy to keep as my baseline?
  • Did the echocardiogram include an estimate of pulmonary artery pressure, and was the right ventricle normal in size and function?
  • Do any of these results need a follow-up test now, such as a high-resolution CT scan, a six-minute walk test or right heart catheterization?
  • How often will the breathing test and echo be repeated, and what change between tests would prompt action?
  • Which symptoms should make me contact the clinic before my next scheduled test?
  • Are there any medicines I take, for scleroderma or anything else, that could affect lung function or interact with treatments being considered?
  • Is acid reflux being assessed and treated, given its possible effect on the lungs?
  • Which vaccinations do you recommend I keep current?
  • Would pulmonary rehabilitation or a supervised exercise program help me, even with normal results?
  • Who coordinates my care between rheumatology, respiratory medicine and cardiology, and how do they share results?
  • If treatment for lung involvement is proposed, what is it intended to do, how will we judge whether it is working, and over what timeframe?

You are entitled to clear answers in plain language. If a result is uncertain, ask what the uncertainty is and what would resolve it. Good teams welcome that question.

When to call your doctor

Routine screening catches slow change. Some changes are not slow, and they should not wait for the next appointment. Contact your care team promptly, or seek urgent medical help where indicated, if you notice any of the following.

  • New or worsening breathlessness, particularly if everyday activities such as climbing a flight of stairs or dressing have become noticeably harder over days or weeks.
  • A persistent dry cough that has lasted more than a few weeks, or a cough that is new and does not fit with a cold.
  • Chest pain or pressure, fainting or near-fainting, especially during exertion. These can signal strain on the right heart and warrant same-day assessment; call emergency services if chest pain is severe or accompanied by collapse.
  • Swelling of the ankles or legs, or a rapid increase in abdominal girth, which can reflect fluid backing up from a struggling right heart.
  • Lips or fingertips turning blue or gray, or a home oxygen reading that is lower than your usual.
  • A racing or irregular heartbeat that is new, persistent or associated with dizziness.
  • Fever with cough or breathlessness, since chest infections can progress quickly in scarred lungs and may need early treatment.
  • A sudden, sharp rise in blood pressure with headache, visual disturbance or reduced urine output. This is a kidney emergency specific to scleroderma, known as scleroderma renal crisis, and requires immediate care.

Trust the pattern of change rather than any single moment. If something feels different from your usual self and you cannot explain it, that is reason enough to call. Clinics managing systemic sclerosis expect these calls and would rather hear from you early than late. Every decision about further testing or treatment that follows rests with the team who knows your history.

Frequently asked questions

Does scleroderma cause lung issues even when I have no breathing symptoms?

Yes. Interstitial lung disease and pulmonary hypertension, the two main chest complications of systemic sclerosis, typically begin without symptoms. Breathlessness tends to appear only after a substantial share of lung reserve is lost, which is why lung function tests and echocardiography are ordered at diagnosis and repeated regularly rather than waiting for a complaint.

How do you confirm pulmonary fibrosis in scleroderma?

A high-resolution CT scan of the chest confirms fibrosis by showing the characteristic patterns, such as reticulation, traction bronchiectasis and, in advanced cases, honeycombing. Lung function tests raise suspicion but cannot see the tissue. A lung biopsy is rarely needed when the CT appearance is typical in someone with established systemic sclerosis.

What is chronic interstitial lung disease?

Interstitial lung disease is inflammation and scarring of the thin tissue between the air sacs where oxygen passes into the blood. Chronic means it is long-lasting and managed over time rather than resolved with a short course of treatment. In scleroderma the pace varies widely, from stable for years to steadily progressive, which repeat testing helps distinguish.

What are the first signs of scleroderma?

The earliest features commonly described by the NHS and Mayo Clinic are Raynaud’s phenomenon, where fingers turn white and then blue in the cold, followed by puffy fingers and skin that gradually thickens and tightens, often over the hands and face. These features are shared with other conditions, so only a clinical assessment with blood tests can establish the diagnosis.

How often should scleroderma pulmonary function tests be repeated?

Rheumatology and respiratory guidelines generally advise lung function testing and echocardiography at diagnosis and then at least yearly, with closer intervals in the first years after diagnosis or when risk factors such as diffuse skin disease or anti-Scl-70 antibodies are present. Your team sets the schedule and may bring a test forward if symptoms change.

Is an echocardiogram for scleroderma painful or risky?

No. A transthoracic echocardiogram uses ultrasound, involves no radiation and causes at most mild pressure from the probe on the chest. Mayo Clinic notes it usually takes under an hour and needs no special preparation. You lie on your side while a technologist records images, then return to normal activity immediately.

What does a low DLCO mean on a scleroderma lung function test?

DLCO measures how well gas crosses from the air sacs into the blood. A low value can reflect scarring of the lung tissue, disease of the small lung blood vessels, anemia or prior smoking. On its own it is a prompt for closer assessment, often a CT scan and a careful look at the echocardiogram, rather than a diagnosis.

Can pulmonary hypertension in scleroderma be diagnosed from the echo alone?

No. The echocardiogram estimates pulmonary artery pressure from blood flow across the tricuspid valve, and that estimate can run high or low. Confirmation requires right heart catheterization, which measures pressure directly and identifies which type of pulmonary hypertension is present. The type matters because different causes are managed differently.

Will I need a lung biopsy to diagnose scleroderma interstitial lung disease?

Rarely. In a person with known systemic sclerosis and a typical high-resolution CT pattern, the diagnosis is usually clear without tissue sampling, and the risks of surgical biopsy generally outweigh the extra information. A biopsy is considered only when the imaging is unusual or another diagnosis needs to be excluded.

Can I develop lung problems with limited scleroderma?

Yes. Limited cutaneous disease carries a lower risk of extensive lung scarring than diffuse disease, but it is associated with a longer-term risk of pulmonary arterial hypertension, particularly in people with anticentromere antibodies. For that reason both lung function tests and echocardiography are recommended for all forms of systemic sclerosis, not only the diffuse subtype.

References

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.

Dr. Şule Eren
Dr. Şule Eren, MD
Author
View profile →
Published November 18, 2026
Keep Reading

More from the Blog

We’re With You at Every Step

How can we help you today?

We value your privacy We use essential cookies to run this site and, with your consent, analytics cookies to understand how it is used and improve it. You can accept, reject, or choose what to allow. See our Cookie Policy.